United Therapeutics (UTHR) Accounts Payables (2009 - 2026)

United Therapeutics has disclosed Accounts Payables across 18 years of filings, most recently posting $498.3 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $498.3 million, up 35.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $498.3 million (up 35.78% YoY), and the FY2025 annual result was $488.0 million, up 41.65% from the prior year.
• Accounts Payables came in at $498.3 million for Q1 2026 at United Therapeutics, up from $488.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $498.3 million in Q1 2026 to a low of $166.4 million in Q1 2022.
• The 5-year median for Accounts Payables is $325.3 million (2024), against an average of $327.5 million.
• Across the five-year window, Accounts Payables gained 0.85% in 2022 and soared 51.48% in 2023, its largest moves.
• United Therapeutics' Accounts Payables stood at $229.9 million in 2022, then advanced by 29.62% to $298.0 million in 2023, then climbed by 15.6% to $344.5 million in 2024, then jumped by 41.65% to $488.0 million in 2025, then gained by 2.11% to $498.3 million in 2026.
• The last three Accounts Payables figures came in at $498.3 million (Q1 2026), $488.0 million (Q4 2025), and $468.0 million (Q3 2025), per Business Quant data.